CANY
VIVO

Caxton Associates (New York)’s Meridian Bioscience Inc VIVO Stock Holding History

Caxton Associates (New York)’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,549
Closed -$715K – 798
2022
Q1 		$715K Buy
+27,549
New +$655K 0.06% 162

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

Caxton Associates (New York)'s VIVO Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Meridian Bioscience Inc (VIVO) in Q2 2022, closing a stake of 27,549 shares — an estimated $715K sold.

Caxton Associates (New York) first reported a position in VIVO in Q1 2022 and held it in 1 quarter. The position peaked at $715K in Q1 2022. 216 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Meridian Bioscience Inc position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 27,549 Meridian Bioscience Inc shares in Q2 2022, an estimated $715K.
  • Caxton Associates (New York) first reported a position in Meridian Bioscience Inc in Q1 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Meridian Bioscience Inc position peaked at $715K in Q1 2022.
  • 216 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.